Addition of galactose-1-phosphate measurement enhances newborn screening for classical galactosemia
© 2022 SSIEM..
Galactosemia is an inborn disorder of carbohydrate metabolism of which early detection can prevent severe illness. Although the assay for galactose-1-phosphate uridyltransferase (GALT) enzyme activity has been available since the 1960s, many issues prevented it from becoming universal. In order to develop the Israeli newborn screening pilot algorithm for galactosemia, flow injection analysis tandem mass spectrometry measurement of galactose-1-phosphate in archived dried blood spots from newborns with classical galactosemia, galactosemia variants, epimerase deficiency, and normal controls, was conducted. Out of 431 330 newborns screened during the pilot study (30 months), two with classical galactosemia and four with epimerase deficiency were identified and confirmed. Five false positives and no false negatives were recorded. Following this pilot study, the Israeli final and routine newborn screening algorithm, as recommended by the Advisory Committee to the National Newborn Screening Program, now consists of galactose-1-phosphate measurement integrated into the routine tandem mass spectrometry panel as the first-tier screening test, and GALT enzyme activity as the second-tier performed to identify only newborns suspected to be at risk for classical galactosemia. The GALT enzyme activity cut-off used in the final algorithm was lowered in order to avoid false positives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Journal of inherited metabolic disease - 46(2023), 2 vom: 13. März, Seite 232-242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daas, Suha [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 05.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jimd.12580 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350270783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350270783 | ||
| 003 | DE-627 | ||
| 005 | 20231226044628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jimd.12580 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350270783 | ||
| 035 | |a (NLM)36515074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daas, Suha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Addition of galactose-1-phosphate measurement enhances newborn screening for classical galactosemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 05.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 SSIEM. | ||
| 520 | |a Galactosemia is an inborn disorder of carbohydrate metabolism of which early detection can prevent severe illness. Although the assay for galactose-1-phosphate uridyltransferase (GALT) enzyme activity has been available since the 1960s, many issues prevented it from becoming universal. In order to develop the Israeli newborn screening pilot algorithm for galactosemia, flow injection analysis tandem mass spectrometry measurement of galactose-1-phosphate in archived dried blood spots from newborns with classical galactosemia, galactosemia variants, epimerase deficiency, and normal controls, was conducted. Out of 431 330 newborns screened during the pilot study (30 months), two with classical galactosemia and four with epimerase deficiency were identified and confirmed. Five false positives and no false negatives were recorded. Following this pilot study, the Israeli final and routine newborn screening algorithm, as recommended by the Advisory Committee to the National Newborn Screening Program, now consists of galactose-1-phosphate measurement integrated into the routine tandem mass spectrometry panel as the first-tier screening test, and GALT enzyme activity as the second-tier performed to identify only newborns suspected to be at risk for classical galactosemia. The GALT enzyme activity cut-off used in the final algorithm was lowered in order to avoid false positives | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a classical galactosemia | |
| 650 | 4 | |a flow injection analysis tandem mass spectrometry | |
| 650 | 4 | |a galactose-1-phosphate | |
| 650 | 4 | |a newborn screening | |
| 650 | 7 | |a galactose-1-phosphate |2 NLM | |
| 650 | 7 | |a 2255-14-3 |2 NLM | |
| 650 | 7 | |a UTP-Hexose-1-Phosphate Uridylyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.10 |2 NLM | |
| 650 | 7 | |a Racemases and Epimerases |2 NLM | |
| 650 | 7 | |a EC 5.1.- |2 NLM | |
| 700 | 1 | |a Abu Salah, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Anikster, Yair |e verfasserin |4 aut | |
| 700 | 1 | |a Barel, Ortal |e verfasserin |4 aut | |
| 700 | 1 | |a Damseh, Nadirah S |e verfasserin |4 aut | |
| 700 | 1 | |a Dumin, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Fattal-Valevski, Aviva |e verfasserin |4 aut | |
| 700 | 1 | |a Falik-Zaccai, Tzipora C |e verfasserin |4 aut | |
| 700 | 1 | |a Habib, Clair |e verfasserin |4 aut | |
| 700 | 1 | |a Josefsberg, Sagi |e verfasserin |4 aut | |
| 700 | 1 | |a Korman, Stanley H |e verfasserin |4 aut | |
| 700 | 1 | |a Kneller, Katya |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Yuval |e verfasserin |4 aut | |
| 700 | 1 | |a Lerman-Sagie, Tally |e verfasserin |4 aut | |
| 700 | 1 | |a Mandel, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Manor, Yehoshua |e verfasserin |4 aut | |
| 700 | 1 | |a Moady Abdalla, Tameemi |e verfasserin |4 aut | |
| 700 | 1 | |a Rock, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Rostami, Nira |e verfasserin |4 aut | |
| 700 | 1 | |a Saada, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Saraf-Levy, Talya |e verfasserin |4 aut | |
| 700 | 1 | |a Shaul Lotan, Nava |e verfasserin |4 aut | |
| 700 | 1 | |a Spiegel, Ronen |e verfasserin |4 aut | |
| 700 | 1 | |a Staretz-Chacham, Orna |e verfasserin |4 aut | |
| 700 | 1 | |a Tal, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Ulanovsky, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Vaisid, Taly |e verfasserin |4 aut | |
| 700 | 1 | |a Wilnai, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Almashanu, Shlomo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of inherited metabolic disease |d 1978 |g 46(2023), 2 vom: 13. März, Seite 232-242 |w (DE-627)NLM000432628 |x 1573-2665 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:2 |g day:13 |g month:03 |g pages:232-242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jimd.12580 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 2 |b 13 |c 03 |h 232-242 | ||